Recruiting

Macugen

Sponsor:

Eyetech Pharmaceuticals

Code:

NCT00354445

Conditions

Age-Related Macular Degeneration (AMD)

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

pegaptanib sodium (Macugen)

Study Details

Brief summary:

The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.

Conditions

Age-Related Macular Degeneration (AMD)

Study ID

NCT00354445

Start date

Jun, 2006

Status verified date

Jan, 2007

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subfoveal CNV secondary to AMD
  • At least 1 but not more than 3 prior treatments for AMD

Exclusion Criteria:

  • Subfoveal scar or subfoveal atrophy
  • Significant media opacities, including cataract, which might interfere with visual acuity

Study Design

Enrollment

1000 participants

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

pegaptanib sodium (Macugen)

Central Contacts and Locations

Central contacts

Macugen Information

1-866-622-8436

Locations

Retina Research Institute of Texas, LLC

Recruiting

Abilene, Texas, United States, 79606

Contacts

Macugen Information

866-622-8436

More Information

Sponsor

Eyetech Pharmaceuticals

Last update posted

Jan 15, 2007

Last verified

Jan, 2007

Keywords

  • Age-Related Macular Degeneration (AMD)
  • pegaptanib sodium
  • subfoveal CNV
  • macugen

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Eyetech Pharmaceuticals on 2007-01-15.